/
We are a medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. We developed the OCS to replace a decades-old standard of care that we believe is significantly limiting access to life-saving transplant therapy for hundreds of thousands of patients worldwide.
17.93% operating margin is respectable but not wide. ROIC at 10.52%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue up 37.1% YoY with margins expanding 9.4pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$636M
▲ +37.1% YoY
Net Income (TTM)
$172M
▲ +436.6% YoY
Op. Margin
14.85%
▲ +9.4pp YoY
ROIC
7.75%
▲ +4.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$151M
▲ +265.0% YoY
Op. Cash Flow (TTM)
$220M
▲ +295.1% YoY
Net Debt
$339M
Cash & Equiv.
$480M
5Y CAGR: +88.2%
Continue Research